Continuous GMP Manufacturing

A recent FDA self-audit revealed that continuous manufacturing (CM) results in faster regulatory approvals and market entry compared to traditional batch-based approaches. CM applications were approved an average of nine months sooner, all in the first review cycle, and reached the market up to 12 months earlier. Benefits included fewer post-approval changes, scalable processes, and support from the FDA’s Emerging Technology Team.

Traditional scale-up introduces delays, quality risks, and costly rework as processes shift from lab to large-scale equipment. Variability, extended timelines, and regulatory hurdles are common and costly. However, with ICM, increased production is achieved by simply running the line for longer periods, removing scale-up activities and their associated risks.

ICM embeds quality into every step of the process. By maintaining tight control of critical parameters and utilizing real-time Process Analytical Technology (PAT), ICM enables continuous monitoring and immediate closed-loop control, thereby minimizing variability and ensuring that critical quality attributes (CQAs) are consistently achieved. Unlike batch systems, where quality is confirmed after production, ICM builds quality throughout the process, reducing the risk of deviation, contamination, and out-of-spec product.

ICM reduces equipment size, eliminates unnecessary unit operations, and minimizes or eliminates downtime between steps. Real-time quality control reduces testing and waste, while continuous operation improves yields and shortens production cycles from months to days. With fewer personnel required, smaller facility footprints, and lower energy and solvent usage, ICM can reduce COGS by ~30–50%.